(MENAFN Editorial)

BaseCase's customer engagement platform will enhance Certara's position as the leading technology-enabled life sciences decision support and consulting organisation.

London, 2nd February 2018 - , the international mergers and acquisitions advisory firm for technology companies, has advised , a data visualisation software as a service (SaaS) company, headquartered in Berlin, Germany, with offices in New York, on its sale to Princeton, New Jersey-based Certara, the global leader in model-informed drug development and regulatory science.

Hampleton Partners logo

The healthcare industry is under increasing pressure to demonstrate the value delivered by new medications and devices. BaseCase's interactive platform improves how life science companies communicate and present that value, whether to C-suite executives, physicians and healthcare providers, or payers and health authorities. This elegant cloud-based solution is ideal for companies seeking to build their own bespoke, branded apps to deliver impactful communication of complex models, analyses, and data. By integrating content creation with sales enablement, it allows users to quickly create and personalize a visual value proposition around a drug or device's ROI and business case.

Miro Parizek, Hampleton principal partner, says: "BaseCase is now part of a company that is an optimal fit and it can focus on further developing its platform and offering. It has been a pleasure to work with BaseCase Co-founder and CEO Gijs Hubben, PhD, and his team, advising them through this game-changing journey and delivering a highly advantageous result for both BaseCase and Certara."

Dr. Hubben emphasises: "Hampleton's team was very experienced and strategic in its approach, constantly hands-on and delivered exactly what it promised from the outset. With a global reach and in-depth understanding of what makes high-technology healthcare businesses special, its team proved informed and creative in everything from initial positioning to final negotiations."

Jonathan Simnett, Hampleton director and industry expert, adds, "This engagement was a typical challenge in which Hampleton excels, as previously separate sectors in the technology economy converge. Success has been achieved through in-depth understanding of how the healthcare industry is under increasing pressure to demonstrate the value delivered by new medications and devices, combined with experience of M&A in the life sciences sector, customer engagement and sales enablement industries."

The project was managed by Jonathan Simnett and Anton Røthe. Financial details about the transaction were not disclosed.

ENDS

About Hampleton Partners
Hampleton Partners is at the forefront of international Mergers and Acquisitions advisory for companies with technology at their core. Hampleton's experienced deal makers have built, bought and sold over 100 fast-growing tech businesses and now provide hands-on expertise and unrivalled international advice to tech entrepreneurs and the companies who are looking to accelerate growth and maximise value.

With offices in London, Frankfurt and San Francisco, Hampleton offers a global perspective with regional and sector expertise in: Automotive Tech, IoT, AI, FinTech, Hi-Tech Industrials, Cybersecurity, VR/AR, HealthTech, Digital Marketing, Enterprise Software, SaaS & Cloud, E-commerce. Download Hampleton's hi-tech sector market analysis reports here: .

Follow Hampleton on and at @TeamHampleton. For more information visit, .

About BaseCase
BaseCase is a Software as a Service (SaaS) solution specialising in building interactive, spreadsheet-driven web-apps for the pharmaceutical, medical device and diagnostic industries. BaseCase provides the technology and consulting expertise to create customisable apps that transform health economic evidence into powerful communication tools. Healthcare enterprise customers benefit from BaseCase's simple development process so that customer-facing representatives can start to improve commercial effectiveness by clearly presenting the clinical and economic value of new pharmaceuticals, devices and diagnostics to payers. BaseCase is headquartered in Berlin, Germany, with offices in New York and Poland. For more information, visit .

About Certara
Certara is a leading decision support technology and consulting organization committed to optimizing drug development and improving health outcomes. Certara's solutions, which span drug discovery through patient care, use the most scientifically-advanced modelling and simulation technologies and regulatory strategies to increase the probability of regulatory and commercial success. Its clients include hundreds of global biopharmaceutical companies, leading academic institutions, and key regulatory agencies. For more information, visit .

Contact
Miro Parizek
Principal Partner

+44 7590 476702

Jonathan Simnett
Director

+44 7976 227224

Jane Henry

+44 789 666 8155

MENAFN300302201800490000ID1096407529